- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02460250
Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death (FIBROSCAME)
According to the French Biomedicine Agency annual report on retrieval activities and transplants, 1,164 liver transplants were performed in 2011 and 1,161 in 2012. If the amount of brain death donors and retrieved liver grafts appears relatively stable, it remains clearly insufficient compared to the increasing number of patients on the waiting list for liver transplantation (2,462 in 2011). The median time on the waiting list before liver transplantation which was established from the cohort of patients registered between 2007 and 2011 (excluding patients registered for emergency transplantation and for living related-donor transplantation) increased significantly from 4.4 months between 2007 and 2009 to 6.6 months between 2010 and 2011. In order to compensate for the lack of liver grafts, donors acceptance criteria were broadened. For example, alternative transplantation lists were created with liver grafts coming from so-called "marginal" donors. However, despite these efforts, livers were retrieved on only two out of three brain death donors, i.e. in 1,572 and 1,589 organ donors in 2011 and 2012, respectively. This is unfortunately not enough to meet the increasing needs in liver grafts and a growing number of patients wait each year for transplant. Strategic lines of improvement were defined in order to meet the "2012-2016 transplant perspective" which targets 5,700 transplants carried out in 2015 (+5% every year, all transplants included, with 5,023 transplants in 2012).
According to the last consensus conference on liver transplantation of the HAS (French High Authority of Health) the assessment of the degree of macrovacuolar and microvacuolar steatosis determines the possibility to retrieve the graft or not. Liver steatosis consists in an accumulation of fatty droplets in hepatocytes. Its prevalence is high, ranging from 16% to 31% in the general population, and increases up to 46% in heavy drinkers and to 50-80% in the obese population. Steatosis results mostly from alcohol consumption and from metabolic syndrome (obesity, type 2 diabetes, hypertriglyceridemia) called non-alcoholic fatty liver disease (NAFLD), and is more rarely secondary to viral hepatitis or exposure to certain medications. NAFLD involves up to 30% of the population in Western countries and its prevalence is increasing. NAFLD may lead to asymptomatic steatosis, but also to steatohepatitis or advanced fibrosis including cirrhosis and its complications Accordingly, the improvement of liver grafts selection based on objective quantitative criteria which takes into account the degree of liver steatosis appears crucial to increase the number of hepatic transplants.
연구 개요
상세 설명
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Amiens, 프랑스, 80054
- University Hospital
-
Angers, 프랑스, 49100
- University Hospital
-
Besançon, 프랑스, 25030
- University Hospital
-
Bordeaux, 프랑스, 33000
- University Hospital
-
Brest, 프랑스, 29200
- University Hospital
-
Caen, 프랑스, 14033
- University Hospital
-
Clermont Ferrand, 프랑스, 63100
- Estaing University Hospital
-
Creteil, 프랑스, 94010
- AP-HP Henri Mondor
-
Grenoble, 프랑스, 38043
- University Hospital
-
Lille, 프랑스, 59037
- University Hospital
-
Limoges, 프랑스, 87042
- University Hospital
-
Lyon, 프랑스, 69004
- Croix Rousse Hospital
-
Nice, 프랑스, 06000
- Nice University Hospital
-
Paris, 프랑스, 84270
- AP-HP Kremlin Bicêtre
-
Poitiers, 프랑스, 86021
- University Hospital
-
Reims, 프랑스, 51100
- Univesity Hospital
-
Rennes, 프랑스, 35033
- University Hospital
-
Tours, 프랑스, 37044
- University Hospital
-
Vandoeuvre-les-nancy, 프랑스, 54500
- University Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients older than 18 years with recognized clinical brain death confirmed by clinical examination, who are considered for organ retrieval and clinically stable to achieve the retrieval procedure
Exclusion Criteria:
- Personal objection to organ retrieval and clinical research expressed during lifetime and registered in the Registre National des Refus (French registration of all refusals to organ donation)
- Family objection to liver retrieval after donor's death
- Ongoing pregnancy when brain death is declared
- For FT and ST measurements included in the panel FibroMaxTM, 4 exclusion criteria are defined specifically (Acute hepatitis or cytolysis with ALT higher than 622 IU/L, acute or chronic hemolysis, extrahepatic cholestasis, sepsis)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Fibroscan
All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.
Liver recipients will be followed up during one year.
Biological and medical data used by all transplant sites for the follow-up of transplant patient will be collected
|
All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Controlled Attenuation Parameter™ (CAP™) measurement
기간: 1 Day
|
Evaluation of the diagnostic accuracy of the CAP™ measured with Fibroscan® to objectively reflect the degree of liver steatosis, a parameter which can be used as an aid in selecting liver grafts before retrieval in donors with brain death (DBD).
|
1 Day
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Liver Stiffness (LS) measurement
기간: 1 Day
|
Evaluation of the diagnostic accuracy of LS measured with Fibroscan® to objectively reflect the degree of fibrosis and steatosis, a parameter which can be used as an aid in selecting liver grafts before retrieval in DBD
|
1 Day
|
Controlled Attenuation Parameter™ (CAP™) measurement
기간: 1 week
|
Determination of the prognostic value of CAP™ in terms of survival of liver grafts at one week after transplantation
|
1 week
|
Liver Stiffness (LS) measurement
기간: 1 week
|
Determination of the prognostic value of LS in terms of survival of liver grafts at one week after transplantation
|
1 week
|
Liver Stiffness (LS) measurement
기간: 1 month
|
Determination of the prognostic value of LS in terms of survival of liver grafts at one month after transplantation
|
1 month
|
Controlled Attenuation Parameter™ (CAP™) measurement
기간: 1 month
|
Determination of the prognostic value of CAP™ in terms of survival of liver grafts at one month after transplantation
|
1 month
|
Liver Stiffness (LS) measurement
기간: 1 year
|
Determination of the prognostic value of LS in terms of survival of liver grafts at one week, one month and one year after transplantation
|
1 year
|
Controlled Attenuation Parameter™ (CAP™) measurement
기간: 1 year
|
Determination of the prognostic value of CAP™ in terms of survival of liver grafts at one week, one month and one year after transplantation
|
1 year
|
Fibrosis measurement
기간: 1 Day
|
evaluate the diagnostic a accuracy of FibroTest in selecting liver grafts before retrieval in DBD by comparing with 1) histological data obtained with liver biopsy (degree of steatosis, degree of fibrosis) and with 2) CAPTM/LS
|
1 Day
|
Steatosis measurement
기간: 1 Day
|
evaluate the diagnostic a accuracy of SteatoTest in selecting liver grafts before retrieval in DBD by comparing with 1) histological data obtained with liver biopsy (degree of steatosis, degree of fibrosis) and with 2) CAPTM/LS
|
1 Day
|
Fibrosis measurement
기간: 1 month
|
Determination of the short-term prognostic values of FibroTest in terms of survival of liver grafts at one month after transplantation
|
1 month
|
Steatosis measurement
기간: 1 month
|
Determination of the short-term prognostic values of SteatoTest in terms of survival of liver grafts at one month after transplantation
|
1 month
|
Fibrosis measurement
기간: 1 year
|
Determination of the short-term prognostic values of FibroTest in terms of survival of liver grafts at one year after transplantation
|
1 year
|
Steatosis measurement
기간: 1 year
|
Determination of the short-term prognostic values of SteatoTest in terms of survival of liver grafts at one year after transplantation
|
1 year
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Nicolas PICHON, MD, University Hospital, Limoges
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- I12033 FIBROSCAME
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Fibroscan에 대한 임상 시험
-
Nanfang Hospital, Southern Medical University모병